IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $50.12 Consensus Price Target from Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have received an average rating of “Moderate Buy” from the sixteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and fourteen have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $50.1250.

Several research firms have recently commented on IDYA. Wall Street Zen downgraded IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Wedbush lifted their price target on IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Truist Financial reduced their price target on IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Friday, July 17th. Finally, Royal Bank Of Canada lowered their price objective on IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 7th.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $38.87 on Friday. The company has a market cap of $3.42 billion, a P/E ratio of -20.04 and a beta of -0.10. The firm’s fifty day moving average price is $35.72 and its two-hundred day moving average price is $32.79. IDEAYA Biosciences has a one year low of $23.23 and a one year high of $40.58.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.16). The company had revenue of $8.86 million for the quarter, compared to the consensus estimate of $8.02 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The business’s quarterly revenue was up 8800.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.88) EPS. As a group, equities research analysts expect that IDEAYA Biosciences will post -4.38 earnings per share for the current year.

Insider Activity at IDEAYA Biosciences

In related news, CAO Briseno Andres Ruiz sold 9,550 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total value of $382,095.50. Following the transaction, the chief accounting officer directly owned 26,466 shares in the company, valued at approximately $1,058,904.66. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.70% of the company’s stock.

Institutional Trading of IDEAYA Biosciences

A number of institutional investors have recently bought and sold shares of IDYA. BlackRock Inc. bought a new stake in shares of IDEAYA Biosciences in the second quarter valued at approximately $331,452,000. Jupiter Topco LLC bought a new position in IDEAYA Biosciences during the 2nd quarter worth $319,728,000. Janus Henderson Group PLC increased its stake in IDEAYA Biosciences by 1.1% during the 1st quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock worth $242,023,000 after acquiring an additional 78,797 shares during the period. Vanguard Group Inc. raised its holdings in IDEAYA Biosciences by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock valued at $173,518,000 after acquiring an additional 97,116 shares in the last quarter. Finally, State Street Corp raised its holdings in IDEAYA Biosciences by 27.6% in the 4th quarter. State Street Corp now owns 4,134,641 shares of the company’s stock valued at $142,935,000 after acquiring an additional 893,707 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.